240 related articles for article (PubMed ID: 23071626)
1. Future impact of various interventions on the burden of COPD in Canada: a dynamic population model.
Najafzadeh M; Marra CA; Lynd LD; Sadatsafavi M; FitzGerald JM; McManus B; Sin D
PLoS One; 2012; 7(10):e46746. PubMed ID: 23071626
[TBL] [Abstract][Full Text] [Related]
2. Projecting Long-term Health and Economic Burden of COPD in the United States.
Zafari Z; Li S; Eakin MN; Bellanger M; Reed RM
Chest; 2021 Apr; 159(4):1400-1410. PubMed ID: 33011203
[TBL] [Abstract][Full Text] [Related]
3. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease.
Hoogendoorn M; Rutten-van Mölken MP; Hoogenveen RT; Al MJ; Feenstra TL
Value Health; 2011 Dec; 14(8):1039-47. PubMed ID: 22152172
[TBL] [Abstract][Full Text] [Related]
4. A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease.
Menn P; Leidl R; Holle R
Pharmacoeconomics; 2012 Sep; 30(9):825-40. PubMed ID: 22799876
[TBL] [Abstract][Full Text] [Related]
5. The burden of COPD in Canada: results from the Confronting COPD survey.
Chapman KR; Bourbeau J; Rance L
Respir Med; 2003 Mar; 97 Suppl C():S23-31. PubMed ID: 12647940
[TBL] [Abstract][Full Text] [Related]
6. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.
Pasquale MK; Sun SX; Song F; Hartnett HJ; Stemkowski SA
Int J Chron Obstruct Pulmon Dis; 2012; 7():757-64. PubMed ID: 23152680
[TBL] [Abstract][Full Text] [Related]
7. The effect of quitting smoking on costs and healthcare utilization in patients with chronic obstructive pulmonary disease: a comparison of current smokers versus ex-smokers in routine clinical practice.
Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Ibáñez-Nolla J
Lung; 2014 Aug; 192(4):505-18. PubMed ID: 24816902
[TBL] [Abstract][Full Text] [Related]
8. Modeling the Health and Economic Burden of Chronic Obstructive Pulmonary Disease in China From 2020 to 2039: A Simulation Study.
Park JE; Zhang L; Ho YF; Liu G; Alfonso-Cristancho R; Ismaila AS; Zafari Z
Value Health Reg Issues; 2022 Nov; 32():8-16. PubMed ID: 35961283
[TBL] [Abstract][Full Text] [Related]
9. A dynamic population model of disease progression in COPD.
Hoogendoorn M; Rutten-van Mölken MP; Hoogenveen RT; van Genugten ML; Buist AS; Wouters EF; Feenstra TL
Eur Respir J; 2005 Aug; 26(2):223-33. PubMed ID: 16055869
[TBL] [Abstract][Full Text] [Related]
10. Contemporary issues in the care of patients with chronic obstructive pulmonary disease.
Urbano FL; Pascual RM
J Manag Care Pharm; 2005 Jun; 11(5 Suppl A):S2-13; quiz S14-6. PubMed ID: 15934804
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of the Evaluation Platform in COPD (EPIC): A Population-Based Outcomes Model of COPD for Canada.
Sadatsafavi M; Ghanbarian S; Adibi A; Johnson K; FitzGerald JM; Flanagan W; Bryan S; Sin D;
Med Decis Making; 2019 Feb; 39(2):152-167. PubMed ID: 30678520
[TBL] [Abstract][Full Text] [Related]
12. The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada.
Maleki-Yazdi MR; Kelly SM; Lam SY; Marin M; Barbeau M; Walker V
Can Respir J; 2012; 19(5):319-24. PubMed ID: 23061077
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives.
Mittmann N; Hernandez P; Mellström C; Brannman L; Welte T
Pharmacoeconomics; 2011 May; 29(5):403-14. PubMed ID: 21504240
[TBL] [Abstract][Full Text] [Related]
14. COPD management costs according to the frequency of COPD exacerbations in UK primary care.
Punekar YS; Shukla A; Müllerova H
Int J Chron Obstruct Pulmon Dis; 2014; 9():65-73. PubMed ID: 24426781
[TBL] [Abstract][Full Text] [Related]
15. Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease.
Atsou K; Chouaid C; Hejblum G
PLoS One; 2011; 6(9):e24870. PubMed ID: 21949774
[TBL] [Abstract][Full Text] [Related]
16. Economic analysis of the Confronting COPD survey: an overview of results.
Wouters EF
Respir Med; 2003 Mar; 97 Suppl C():S3-14. PubMed ID: 12647938
[TBL] [Abstract][Full Text] [Related]
17. The burden of COPD in Italy: results from the Confronting COPD survey.
Dal Negro R; Rossi A; Cerveri I
Respir Med; 2003 Mar; 97 Suppl C():S43-50. PubMed ID: 12647942
[TBL] [Abstract][Full Text] [Related]
18. The projected economic and health burden of sub-optimal asthma control in Canada.
Zafari Z; Sadatsafavi M; Chen W; FitzGerald JM
Respir Med; 2018 May; 138():7-12. PubMed ID: 29724396
[TBL] [Abstract][Full Text] [Related]
19. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
[TBL] [Abstract][Full Text] [Related]
20. The burden of COPD in Spain: results from the Confronting COPD survey.
Izquierdo JL
Respir Med; 2003 Mar; 97 Suppl C():S61-9. PubMed ID: 12647944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
